BlueCrest Capital Management’s Charles River Laboratories CRL Stock Holding History

BlueCrest Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,006	Closed	-$540K	–	943
2017 Q1	$540K	Buy	+6,006	New	+$510K	0.03%	416
2016 Q3	–	Sell	-3,013	Closed	-$248K	–	783
2016 Q2	$248K	Buy	+3,013	New	+$248K	0.01%	742
2016 Q1	–	Sell	-51,949	Closed	-$4.18M	–	829
2015 Q4	$4.18M	Buy	+51,949	New	+$3.75M	0.17%	136
2015 Q2	–	Sell	-17,671	Closed	-$1.4M	–	809
2015 Q1	$1.4M	Buy	+17,671	New	+$1.3M	0.08%	318

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlueCrest Capital Management's CRL Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Charles River Laboratories (CRL) in Q2 2017, closing a stake of 6,006 shares — an estimated $540K sold.

BlueCrest Capital Management first reported a position in CRL in Q1 2015 and held it in 4 quarters. The position peaked at $4.18M in Q4 2015. 302 funds tracked by Wall St. Rank hold CRL as of Q2 2017.

BlueCrest Capital Management reported no remaining Charles River Laboratories position as of Q2 2017 after selling out during the quarter.
BlueCrest Capital Management sold 6,006 Charles River Laboratories shares in Q2 2017, an estimated $540K.
BlueCrest Capital Management first reported a position in Charles River Laboratories in Q1 2015 and held it in 4 quarters.
BlueCrest Capital Management's Charles River Laboratories position peaked at $4.18M in Q4 2015.
302 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.